Immuron Ltd has announced its Annual General Meeting (AGM) scheduled for November 18, 2026. This meeting is significant as it will address several important resolutions, including the adoption of the remuneration report and the re-election of a director. The AGM reflects Immuron's commitment to corporate governance and transparency in its operations.
Immuron Ltd, based in Carlton, Victoria, is classified under the SIC code 2834, which pertains to Pharmaceutical Preparations. The company trades on the Nasdaq under the ticker IMRN. This filing is part of its ongoing compliance with regulatory requirements, as evidenced by its recent filings, including a 6-K on October 16, 2026.
The filing details the agenda for the upcoming AGM, including:
“Notice of Annual General Meeting and Proxy Form.”
Shareholders will have the opportunity to consider and vote on several resolutions, which include:
- Adoption of the Remuneration Report for the year ended June 30, 2026.
- Re-election of Dr. Jeannette Anne Joughin as a Non-Executive Director.
- Approval of increased placement capacity for equity securities.
- Renewal of the Omnibus Incentive Plan.
- Election of Mr. Param Lally as a Non-Executive Director.
This AGM may affect shareholders, company management, and stakeholders involved in Immuron's operations. The resolutions proposed are vital for the company’s governance and future direction.
Looking ahead, the company will proceed with the AGM on November 18, 2026, as outlined in the filing. Shareholders are encouraged to participate either in person or by proxy to ensure their voices are heard on these significant matters.